Xbrane Biopharma AB (OSTO:XBRANE)

kr 0.2295 0.0391 (20.54%) Market Cap: 351.02 Mil Enterprise Value: 517.09 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 40/100

Q4 2023 Xbrane Biopharma AB Earnings Call Transcript
Feb 26, 2024

kr0.7 (-4.89%)

Earnings
Q4 2022 Xbrane Biopharma AB Earnings Call Transcript
Feb 17, 2023

kr10.28 (-4.12%)

Earnings
Xbrane Biopharma AB at Redeye investor forum online 2022 Transcript
Aug 31, 2022
Q1 2022 Xbrane Biopharma AB Earnings Call Transcript
May 05, 2022

kr9.82 (-1.59%)

Earnings
Q4 2021 Xbrane Biopharma AB Earnings Call Transcript
Feb 24, 2022

kr9.94 (-1.35%)

Earnings
Xbrane Biopharma press conference two new biosimilar candidates Transcript
Dec 14, 2021
Xbrane Biopharma at redeye investor forum Malmo 2021 Transcript
Dec 09, 2021
Xbrane Biopharma at Redeye life science day 2021 Transcript
Nov 16, 2021
Q2 2021 Xbrane Biopharma AB Earnings Call Transcript
Aug 13, 2021

kr17.03 (+2.88%)

Earnings

Q2 2021 Xbrane Biopharma AB Earnings Call Transcript

Aug 13, 2021 / 08:00AM GMT

Release Date Price: kr17.03 (+2.88%)

Transcript

Martin Amark;publ;CEO

Xbrane Biopharma AB

()-

Thank you very much, and hello, everybody. Thanks for calling in. We are here to present the Q2 report of Xbrane Biopharma, and we go to page 3. So just going through some of the highlights of the second quarter of 2021, we can start with our Xlucane program, our biosimilar candidate to Lucentis. We were pleased to receive a positive topline data from the interim readout which we did in the ongoing pivotal Phase 3 trial. And that then triggered a confirmation of our plan to submit the marketing authorization application to EMA, the European regulatory authority, and that will be done next month. It's practically finalized. We worked a lot with that document throughout the year but intensively during the summer, and it will be submitted during the course of September.

When it comes to the Biologics License Application to FDA in the US, it's now planned for the fourth quarter of this year, but we are going to have a meeting with the FDA in August where that exact plan and the final date will be confirmed, a final date

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.